Camptothecin derivatives as chemoradiosensitizing agents

Details Camptothecin derivatives as chemoradiosensitizing agents Camptothecin derivatives as chemoradiosensitizing agents

2011-01-25

2011-01-25

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C546S048000

Reexamination Certificate

active

07875602

ABSTRACT:
Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

REFERENCES:
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 4663161 (1987-05-01), Mannino et al.
patent: 4727068 (1988-02-01), Abrams et al.
patent: 4797397 (1989-01-01), Suto et al.
patent: 4921963 (1990-05-01), Skov et al.
patent: 4927941 (1990-05-01), Kagiya et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 4945102 (1990-07-01), Suzuki et al.
patent: 4954515 (1990-09-01), Suto
patent: 4977273 (1990-12-01), Kagiya et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5026694 (1991-06-01), Skov et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5036096 (1991-07-01), Suto
patent: 5041653 (1991-08-01), Lee et al.
patent: 5043165 (1991-08-01), Radhakrishnan
patent: 5064849 (1991-11-01), Suzuki et al.
patent: 5077057 (1991-12-01), Szoka, Jr.
patent: 5175278 (1992-12-01), Peik et al.
patent: 5175287 (1992-12-01), Lee et al.
patent: 5196413 (1993-03-01), Teicher et al.
patent: 5294715 (1994-03-01), Papadopoulou-Rosenzweig et al.
patent: 5304654 (1994-04-01), Kagiya et al.
patent: 5342959 (1994-08-01), Beylin et al.
patent: 5549910 (1996-08-01), Szoka, Jr.
patent: 5552156 (1996-09-01), Burke
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5718914 (1998-02-01), Foldvari
patent: 5736156 (1998-04-01), Burke
patent: 5783211 (1998-07-01), Manzo et al.
patent: 5827533 (1998-10-01), Needham
patent: 5874105 (1999-02-01), Watkins et al.
patent: 5882679 (1999-03-01), Needham
patent: 5916896 (1999-06-01), Wall et al.
patent: 5935949 (1999-08-01), White
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 5981542 (1999-11-01), Bigg et al.
patent: 6028078 (2000-02-01), Hausheer et al.
patent: 6040313 (2000-03-01), Wall et al.
patent: 6057303 (2000-05-01), Haridas et al.
patent: 6060604 (2000-05-01), Yang et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6114529 (2000-09-01), Kawaguchi et al.
patent: 6120793 (2000-09-01), Cao et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6207832 (2001-03-01), Curran et al.
patent: 6281223 (2001-08-01), Choy et al.
patent: 6339091 (2002-01-01), Bigg et al.
patent: 6350756 (2002-02-01), Yang et al.
patent: 6403604 (2002-06-01), Yang et al.
patent: 6423707 (2002-07-01), Yang et al.
patent: 6492335 (2002-12-01), Lerchen et al.
patent: 6506734 (2003-01-01), Lerchen et al.
patent: 6855720 (2005-02-01), Yang
patent: 6933302 (2005-08-01), Yang
patent: 2002/0040155 (2002-04-01), Holton et al.
patent: 2003/0138432 (2003-07-01), Glazier
patent: 0861842 (2003-11-01), None
patent: WO 95/10304 (1995-04-01), None
patent: WO 96/26950 (1996-09-01), None
patent: WO 97/19085 (1997-05-01), None
patent: WO 97/28165 (1997-08-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/14190 (1998-04-01), None
patent: WO 98/35940 (1998-08-01), None
patent: WO 99/17805 (1999-04-01), None
patent: WO 00/66127 (2000-11-01), None
patent: WO 00/67801 (2000-11-01), None
patent: WO 03/014069 (2003-02-01), None
Cannon, J.G., Chapter 19 of Burger's Medicinal Chemistry and Drug Discovery, vol. I: Principles and Practice Wiley Interscience, 5thEdition, p. 783-802, 1995.
Horig et al ‘From bench to clinic and back: Perspective on the 1stIQPC Translational Research Conference’ Journal of Translational Medicine, 2(44), p. 1-8, 2004.
Schafer et al ‘Failure is an option: learning from unsuccessful proof-of-concept trials’ Drug Discovery Today, 13(21/22),p. 913-916, 2008.
Adams, “The Impact of Tumor Physiology on Camptothecin-Based Drug Development.”Curr. Med. Chem.—Anti-Cancer Agents, Jan. 2005, 5(1),1-13.
Driver et al. “Synthesis and Pharmacology of New Camptothecin Drugs.”Mini-Reviews in Medicinal Chemistry, May 2005, 5(5):425-439.
Jaklevic et al. “Relative Contribution of DNA Repair, Cell Cycle Checkpoints, and Cell Death to Survival After DNA Damage inDrosophilaLarvae.”Current Biology, Jan. 2004, 14(1):23-32.
Armstrong DK. “Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity”,The Oncologist2004; 9(1):33-42.
Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P. “Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: Results of a French Society of Paediatric Oncology Phase II Study”.Cancer, 2005;104(12):2792-7.
Chastagner P, Merlin JL, Marchal C, Hoffstetter S, Barberi-Heyob M, Vassel G, Duprez A. “In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice”Clin Cancer Res.2000; 6(8):3327-3333.
Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M. “Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas”Hum Pathol.2004; 35(6):745-51.
Hartmann JT, Lipp HP. “Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II—mechanisms of action, pharmacokinetics and toxicity profile”,Drug Safety, 2006; 29(3):209-30.
Hecht SM. “Camptothecin: roles of the D and E rings in binding to the topoisomerase I-DNA covalent binary complex”,Curr. Med Chem. Anticancer Agents; 2005; 5(4):353-362.
Holm C, Covey J.M., Kerrigan D., Pommier Y., “Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells”,Cancer Res.1989;49(22):6365-6368.
Hsiang Y.H., Lihou M.G., Liu L.F. “Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin”Cancer Res.1989, 49(18):5077-82.
Husain, I.; Mohler, JL.; Seigler, HF.; Besterman, JM, “Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy”,Cancer Res.1994, 54, 539-546.
Lamond JP, Wang M, Kinsella TJ, Boothman DA, “Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors”.Int. J Radiat. Oncol. Biol Phys.1996;36(2):369-76.
Lamond, JP, Wang, M, Kinsella, TJ, Boothman, DA, “Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation”,Int. J. Radiat. Oncol Biol Phys.1996; 36(2):361-8.
Marchesini, R, Colombo, A, Caserini, C, Perego, P, Supino, R, Capranico, G Tronconi, M, Zunino, F., “Interaction of ionizing radiation with topotecan in two human tumor cell lines”,Int. J Cancer, 1996;66(3):342-346.
Omura M, Torigoe S, Kubota N. “SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids”.Radiother Oncol.1997; 43(2):197-201.
Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E, Colucci G.. “Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients”,Int. J Cancer. 2004;111(2):252-2588.
Adams, D.J. et al. “Camptothec

Affiliated with

Also associated with

Rating

Camptothecin derivatives as chemoradiosensitizing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Camptothecin derivatives as chemoradiosensitizing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin derivatives as chemoradiosensitizing agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2743809